Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Acusphere, Nycomed Group A/S deal

Nycomed licensed from ACUS exclusive European rights to develop and market AI-700, a synthetic

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE